American Heart Journal
Volume 141, Issue 2, Supplement , Pages S22-S25 , February 2001

Drug therapy or coronary angioplasty for the treatment of coronary artery disease: New insights

References 

  1. Windecker S, Meyer BJ, Bonzel T. Interventional cardiology in Europe 1994. Working Group Coronary Circulation of the European Society of Cardiology. Eur Heart J. 1998;19:40–54
  2. Hueb WA, Bellotti G, Almeida de Oliveira S. The Medicine, Angioplasty or Surgery Study (MASS): a prospective, randomized trial of medical therapy, balloon angioplasty or bypass surgery for single proximal left anterior descending artery stenoses. J Am Coll Cardiol. 1995;26:1600–1605
  3. Parisi AF, Folland ED, Hartigan P, on behalf of the Veterans Affairs ACME investigators . A comparison of angioplasty with medical therapy in the treatment of single-vessel coronary artery disease. N Engl J Med. 1992;326:10–16
  4. The RITA-2 trial participants . Coronary angioplasty versus medical therapy for angina: the second Randomised Intervention Treatment of Angina (RITA-2) Trial. Lancet. 1997;350:461–468
  5. The Scandinavian Simvastatin Survival Study Group . A randomised trial of cholesterol lowering in 4444 patients with coronary artery disease: The Scandinavian Simvastatin Survival Study Trial (4S). Lancet. 1994;344:1383–1389
  6. Gould KL. New concepts and paradigms in cardiovascular medicine: the non-invasive management of coronary artery disease. Am J Med. 1998;104:2S–17S
  7. Ganz P, Creager MA, Fang JC. Pathogenic mechanisms of atherosclerosis: effect of lipid lowering on the biology of atherosclerosis. Am J Med. 1996;101:10S–16S
  8. Eichstädt HW, Eskötter H, Hoffman I. Improvement of myocardial perfusion by short-term fluvastatin therapy in coronary artery disease. Am J Cardiol. 1995;76:122A–125A
  9. Siebelink HMJ, van Boven AJ, Blanksma PK. Cholesterol lowering in primary prevention improves coronary flow reserve and vascular resistances [abstract]. Circulation. 1998;98(suppl 1):I-95
  10. Brown BG, Zhao XQ. Importance of endothelial function in mediating the benefits of lipid-lowering therapy. Am J Cardiol. 1998;82:49T–52T
  11. Treasure CB, Llein JL, Weintraub WS. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med. 1995;332:481–487
  12. Andrews TC, Raby K, Barry J. Effect of cholesterol reduction on myocardial ischemia in patients with coronary disease. Circulation. 1997;95:324–328
  13. Gibbons GH. Endothelial function as a determinant of vascular function and structure: a new therapeutic target. Am J Cardiol. 1997;79:3–8
  14. Fuster V. Human lesion studies. Ann NY Acad Sci. 1997;811:207–224
  15. Bustos C, Hernandez Presa MA, Ortego M. HMG-coA reductase inhibition by atorvastatin in a rabbit model of atherosclerosis reduces neointimal inflammation. Am J Coll Cardiol. 1998;32:2057–2064
  16. Aikawa M, Rabkin E, Okada Y. Lipid lowering by diet reduces matrix metalloproteinase activity and increases collagen content of rabbit atheroma: a potential mechanism of lesion stabilization. Circulation. 1998;97:2433–2444
  17. Kockx MM, De Meyer GR, Buyssens N. Cell composition, replication and apoptosis in atherosclerotic plaques after 6 months of cholesterol withdrawal. Circ Res. 1998;83:378–387
  18. Libby P, Aikawa M. New insights into plaque stabilization by lipid lowering. Drugs. 1998;56(suppl 1):9–13
  19. Jukema JW, Bruschke AVG, van Boven AJ, on behalf of the REGRESS study group . Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels: the Regression Growth Evaluation Statin Study (REGRESS). Circulation. 1995;91:2528–2540
  20. van Boven AJ, Jukema JW, Zwinderman AH. Reduction of transient myocardial ischemia with pravastatin in addition to the conventional treatment in patients with angina pectoris. Circulation. 1996;94:1503–1505
  21. Lerman A, Cannan CR, Higano SH. Coronary vascular remodelling in association with endothelial dysfunction. Am J Cardiol. 1998;81:1105–1109
  22. Mulder HJGH, Jukema JW, Bal ET. Pravastatin reduces both clinical and angiographic restenosis two years after percutaneous transluminal coronary angioplasty: an analysis of the PTCA stratum of the REGRESS study [abstract]. J Am Coll Cardiol. 1999;33(suppl A):79A
  23. Callister TQ, Raggi P, Cooil B. Effect of HMG-coA reductase inhibitors on coronary artery disease as assessed by electron-beam computed tomography. N Engl J Med. 1998;339:1972–1978
  24. McCormick LS, Black DM, Waters D. Rationale, design and baseline characteristics of a trial comparing aggressive lipid lowering with atorvastatin versus angioplasty treatments (AVERT). Am J Cardiol. 1997;80:1130–1133
  25. Pitt B, Waters D, Brown V. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. N Engl J Med. 1999;341:70–76

☆ Reprint requests: Giovanni Amoroso, MD, Thoraxcentre, Academisch Ziekenhuis Groningen, Postbus 30 001, 9700 RB Groningen, The Netherlands. E-mail: G.Amoroso@thorax.azg.nl

PII: S0002-8703(01)70040-3

American Heart Journal
Volume 141, Issue 2, Supplement , Pages S22-S25 , February 2001

Article Tools